期刊文献+

应用多维度智能化平台提高儿童皮下免疫治疗依从性的研究 被引量:1

Evaluation of multi-dimensional intelligent management in improving compliance of subcutaneous specific immunotherapy in children
下载PDF
导出
摘要 目的探讨多维度智能化平台对提高儿童皮下免疫治疗(SCIT)的治疗依从性的效果。方法选取被诊断为变应性鼻炎(AR)和(或)过敏性哮喘(AS)并接受SCIT的162例患儿为研究对象,在常规处理基础上增加多维度智能化平台干预的85例患儿被纳入智能组,仅予常规处理的77例患儿被纳入传统组。比较2组患儿初始治疗阶段脱落率、进入维持治疗阶段所用时间,对患儿进行SCIT疗效评估,包括AR症状评分、AS日间及夜间症状评分、疼痛视觉模拟评分法(VAS)评分及药物评分,比较2组各量表评分在开始SCIT时及进入维持治疗阶段时的改善情况,并比较2组的满意度。结果智能组和传统组患儿SCIT的初始治疗阶段脱落率比较差异有统计学意义(0.0%vs.7.8%,P<0.01)。智能组达到维持治疗阶段所用时间短于传统组[15(15,16)周vs.16(15,18)周,P<0.01]。进入维持治疗阶段时智能组AR症状评分、AS日间及夜间症状评分、VAS、药物评分及满意度均优于传统组(P均<0.01)。结论多维度智能化平台有助于提高接受SCIT患儿的治疗依从性、缩短进入维持治疗阶段所用时间、提高治疗效果及患者满意度。 Objective To evaluate the effect of multi-dimensional intelligent management on improving the compliance of subcutaneous specific immunotherapy(SCIT)in children.Methods 162 children diagnosed with allergic rhinitis(AR)and(or)allergic asthma(AS)receiving SCIT were recruited in this study.85 children received routine management combined with multi-dimensional intelligent management were assigned into the intelligent group and 77 children received routine management were allocated into the control group.The SCIT shedding rate in the initial treatment stage and the time taken to reach the maintenance phase were compared between two groups.The clinical efficacy of SCIT in children was assessed by the symptom score for AR,AS symptom scores(daytime and nighttime),visual analogue scale(VAS)score and medication score were compared between two groups.The improvement of the scores of each scale from the beginning of SCIT to the maintenance treatment was evaluated and compared between two groups.The degree of satisfaction was also statistically compared between two groups.Results There were significant differences in shedding rate during the initial treatment stage(0.0%vs.7.8%,P<0.01),the time taken to reach the maintenance treatment stage(15(15,16)weeks vs.16(15,18)weeks,P<0.01)between two groups.The symptom score for AR,AS symptom scores(daytime and nighttime),VAS score,medication score and degree of satisfaction in the intelligent group were superior to those in the control group(all P<0.01).Conclusion Application of multi-dimensional intelligent management contributes to improving the compliance of SCIT,shortening the time taken to reach the maintenance phase,enhancing clinical efficacy and degree of satisfaction in children with airway allergic diseases.
作者 杨丽芬 张萍萍 潘莉 施欣 黎雅婷 温燕铭 袁玉芳 陈壮桂 钟鑫琪 Yang Lifen;Zhang Pingping;Pan Li;Shi Xin;Li Yating;Wen Yanming;Yuan Yufang;Chen Zhuanggui;Zhong Xinqi(Department of Pediatrics,the Third Affiliated Hospital of Guangzhou Medical University,Guangzhou 510145,China;Department of Pediatrics,the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,China)
出处 《新医学》 CAS 2022年第2期98-103,共6页 Journal of New Medicine
基金 广东省医学科学技术研究基金(A2021386,A2020232) 广州市产学研协同创新重大专项民生科技研究(201704020179)。
关键词 皮下免疫治疗 智能化平台 儿童 治疗依从性 变应性鼻炎 过敏性哮喘 Subcutaneous specific immunotherapy Multi-dimensional intelligent management Children Treatment compliance Allergic rhinitis Allergic asthma
  • 相关文献

参考文献7

二级参考文献70

  • 1顾之燕,董震.变应性鼻炎的诊治原则和推荐方案(2004年,兰州)[J].中华耳鼻咽喉头颈外科杂志,2005,40(3):166-167. 被引量:1708
  • 2Incorvaia C,Frati F. One century of allergen-specific immunotherapyfor respiratory allergy[J].{H}Immunotherapy,2011,(05):629-635.
  • 3中华医学会儿科学分会呼吸学组.儿童支气管哮喘诊断与防治指南(2008年修订)[J]{H}中华儿科杂志,2008(46):745-753.
  • 4Tabar AI,Arroabarren E,Echechipía S. Three yeas of specific immunotherapy may besufficient in house dust mite respiratory allergy[J].{H}Journal of Allergy and Clinical Immunology,2011,(01):57-63.
  • 5Tunlersley MS,Butler KK,Butler WK. Local reactions during allergen immunotherapy do not require dose adjustment[J].{H}Allergy and Clinical Immunology International,2000.840-843.
  • 6Amin HS,Liss GM,Bernstein DI. Evaluation of near-futal reactions to allergen immunotherapy injections[J].{H}Allergy and Clinical Immunology International,2006.169-175.
  • 7Alvarez-Cuesta E,J Bousquet J,Canonica GW. Standards for practical allergen-specific immunotherapy[J].{H}ALLERGY,2006,(Suppl 82):1-20.doi:10.1111/j.1398-9995.2006.01219_1.x.
  • 8Canonica GW,Baena-Cagnani CE,Bousquet J. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy.A statement of a World Allergy Organization(WAO)taskforce[J].{H}ALLERGY,2007.317-324.
  • 9Bousquet J,Khaltaev N,Cruz AA. Allergic Rhinitis and its Impact on Asthma(ARIA)2008 update(in collaboration with the World Health Organization,GA (2)LEN and AllerGen)[J].{H}ALLERGY,2008,(Suppl 86):8-160.
  • 10PAWANKAR R,CANONICA G W,HOLGATE S T,et al.World Allergy Organization(WAO)White Book on Allergy[J].World allergy organization Journal,2011:1-126.

共引文献108

同被引文献23

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部